User login
Lewis Blevins, MD; Richard Auchus, MD, PhD; David Brown, MD, PhD; Amir Hamrahian, MD; and Smita Kargutkar, MD share their insights and real-world perspectives on hypercortisolism diagnosis and management, including:
• The understanding of hypercortisolism has evolved significantly over the past decades to extend beyond classic physical manifestations (e.g., central obesity, facial plethora, buffalo hump, purple striae)
• Early identification of patients with mild autonomous cortisol secretion is important as hypercortisolism can lead to age-inappropriate and treatment-resistant metabolic syndrome
• Patient identification and management approaches for hypercortisolism can differ between academic and community settings due to differences in available resources and multidisciplinary management teams
• Educating primary care providers and community endocrinologists about the consequences of hypercortisolism can be beneficial in bridging the gap between academic and community settings
Lewis Blevins, MD |
Richard Auchus, MD, PhD
|
David Brown, MD, PhD
|
Amir Hamrahian, MD |
Smita Kargutkar, MD |
Click HERE to read the supplement.
©2022 Corcept Therapeutics Incorporated. All Rights Reserved. DSE-00997 DEC 2022
Lewis Blevins, MD; Richard Auchus, MD, PhD; David Brown, MD, PhD; Amir Hamrahian, MD; and Smita Kargutkar, MD share their insights and real-world perspectives on hypercortisolism diagnosis and management, including:
• The understanding of hypercortisolism has evolved significantly over the past decades to extend beyond classic physical manifestations (e.g., central obesity, facial plethora, buffalo hump, purple striae)
• Early identification of patients with mild autonomous cortisol secretion is important as hypercortisolism can lead to age-inappropriate and treatment-resistant metabolic syndrome
• Patient identification and management approaches for hypercortisolism can differ between academic and community settings due to differences in available resources and multidisciplinary management teams
• Educating primary care providers and community endocrinologists about the consequences of hypercortisolism can be beneficial in bridging the gap between academic and community settings
Lewis Blevins, MD |
Richard Auchus, MD, PhD
|
David Brown, MD, PhD
|
Amir Hamrahian, MD |
Smita Kargutkar, MD |
Click HERE to read the supplement.
©2022 Corcept Therapeutics Incorporated. All Rights Reserved. DSE-00997 DEC 2022
Lewis Blevins, MD; Richard Auchus, MD, PhD; David Brown, MD, PhD; Amir Hamrahian, MD; and Smita Kargutkar, MD share their insights and real-world perspectives on hypercortisolism diagnosis and management, including:
• The understanding of hypercortisolism has evolved significantly over the past decades to extend beyond classic physical manifestations (e.g., central obesity, facial plethora, buffalo hump, purple striae)
• Early identification of patients with mild autonomous cortisol secretion is important as hypercortisolism can lead to age-inappropriate and treatment-resistant metabolic syndrome
• Patient identification and management approaches for hypercortisolism can differ between academic and community settings due to differences in available resources and multidisciplinary management teams
• Educating primary care providers and community endocrinologists about the consequences of hypercortisolism can be beneficial in bridging the gap between academic and community settings
Lewis Blevins, MD |
Richard Auchus, MD, PhD
|
David Brown, MD, PhD
|
Amir Hamrahian, MD |
Smita Kargutkar, MD |
Click HERE to read the supplement.
©2022 Corcept Therapeutics Incorporated. All Rights Reserved. DSE-00997 DEC 2022